PI3K Inhibitors for HR+ Metastatic Breast Cancer
3 Visualizações
• 07/03/23
0
0
Embutir
administrator
Assinantes
Panelists Adam M. Brufsky, MD, PhD; José Baselga, MD, PhD; Carlos L. Arteaga, MD; Debu Tripathy, MD; and Denise A. Yardley, MD, discuss the potential for use of PI3K inhibitors buparlisib, alpelisib, and taselisib and their anticipation of data coming in the near future for breast cancer.
Mostre mais
Comentários do Facebook
SORT BY-
Melhores Comentários
-
Últimos Comentários